TIM3 comes of age as an inhibitory receptor

Y Wolf, AC Anderson, VK Kuchroo - Nature Reviews Immunology, 2020 - nature.com
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

[HTML][HTML] Resistance to checkpoint inhibition in cancer immunotherapy

L Barrueto, F Caminero, L Cash, C Makris… - Translational …, 2020 - Elsevier
The interaction of the host immune system with tumor cells in the tissue microenvironment is
essential in understanding tumor immunity and development of successful cancer …

TIM-3: An update on immunotherapy

L Zhao, S Cheng, L Fan, B Zhang, S Xu - International …, 2021 - Elsevier
T cell immunoglobulin and mucin domain 3 (TIM-3) was originally found to be expressed on
the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to …

Immune checkpoint inhibitors in human glioma microenvironment

A Ghouzlani, S Kandoussi, M Tall, KP Reddy… - Frontiers in …, 2021 - frontiersin.org
Gliomas are the most common primary brain tumors in adults. Despite the fact that they are
relatively rare, they cause significant morbidity and mortality. High-grade gliomas or …

Functions of immune checkpoint molecules beyond immune evasion

Y Zhang, J Zheng - Regulation of cancer immune checkpoints: molecular …, 2020 - Springer
Immune checkpoint molecules, including inhibitory and stimulatory immune checkpoint
molecules, are defined as ligand–receptor pairs that exert inhibitory or stimulatory effects on …

Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas

JE Kim, MA Patel, A Mangraviti, ES Kim… - Clinical Cancer …, 2017 - AACR
Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin
mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of …

Emerging targets in cancer immunotherapy

S Burugu, AR Dancsok, TO Nielsen - Seminars in cancer biology, 2018 - Elsevier
The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1)
targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor …

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

YH Huang, C Zhu, Y Kondo, AC Anderson, A Gandhi… - Nature, 2015 - nature.com
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an
activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell …

The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity

A Schnell, L Bod, A Madi, VK Kuchroo - Cell research, 2020 - nature.com
Co-inhibitory receptors are important regulators of T-cell function that define the balance
between tolerance and autoimmunity. The immune regulatory function of co-inhibitory …

Prospects of immune checkpoint modulators in the treatment of glioblastoma

M Preusser, M Lim, DA Hafler, DA Reardon… - Nature Reviews …, 2015 - nature.com
Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even
with the current gold-standard first-line treatment—maximal safe resection and combination …